3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Multiple Myeloma
7
Lymphoma, B-Cell
5
Pancreatic Neoplasms
4
Lymphoma, Non-Hodgkin
4
Lymphoma, Large B-Cell, Diffuse
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Carcinoma, Hepatocellular
4
Stomach Neoplasms
3
Lymphoma, Mantle-Cell
3
Lymphoma, Follicular
3
Glioma
3
Burkitt Lymphoma
3
Recurrence
2
Neoplasms
2
Melanoma
2
Lymphoma
2
Lung Neoplasms
2
Leukemia, Prolymphocytic, B-Cell
2
Leukemia, Myeloid, Acute
2
Leukemia, Myeloid
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Simpson-Golabi-Behmel syndrome
1
Sarcoma, Synovial
1
Prostatic Neoplasms
1
Plasmacytoma
1
Pelvic Neoplasms
1
Interventions
Gemcitabine
3
ensituximab
1
Lead
1
Immunotherapy, Adoptive
1
Cetuximab
1
Bevacizumab
1
Atu027
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Pancreatic Ductal
×
Immunotherapy, Adoptive
×
Clear all
NCT07153289
2025-09-03
ResCPa
University Hospital Tuebingen
Phase 1/2
Not yet recruiting
38 enrolled